Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition

Eisai has agreed to pay $325 million for Morphotek, a small biopharmaceutical company with proprietary discovery technologies and an oncology pipeline, the companies announced March 22. The deal is expected to close during Eisai's first quarter of 2007, which begins April 1